



US007060276B2

(12) **United States Patent**
Lanar et al.

(10) **Patent No.:** **US 7,060,276 B2**
(45) **Date of Patent:** **Jun. 13, 2006**

(54) **PLASMODIUM FALCIPARUM AMA-1
PROTEIN AND USES THEREOF**

(75) Inventors: **David E. Lanar**, Takoma Park, MD
(US); **Sheetij Dutta**, Silver Spring, MD
(US); **Lisa A. Ware**, Silver Spring, MD
(US); **Lalitha P. V. Nair**, Silver Spring,
MD (US)

(73) Assignee: **The United States of America as
represented by the Secretary of the
Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/105,717**

(22) Filed: **Mar. 25, 2002**

(65) **Prior Publication Data**

US 2003/0032787 A1 Feb. 13, 2003

Related U.S. Application Data

(60) Provisional application No. 60/278,616, filed on Mar.
26, 2001.

(51) **Int. Cl.**

A61K 39/00 (2006.01)
A61K 39/15 (2006.01)
C07H 21/04 (2006.01)
C12N 15/63 (2006.01)
C12N 15/09 (2006.01)

(52) **U.S. Cl.** **424/184.1**; 424/268.1;
435/69.1; 435/69.3; 435/69.7; 435/71.2; 435/235.1;
435/320.1; 435/70.1; 435/70.2; 536/23.5;
536/23.7; 536/24.32

(58) **Field of Classification Search** 435/69.1,
435/69.3, 69.7, 71.2, 235.1, 320.1, 70.1,
435/70.2, 7, 71.1; 536/23.5, 23.7, 24.32,
536/23.1; 424/268.1, 184.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,766,597 A 6/1998 Paoletti et al.
6,417,341 B1 7/2002 Anders et al.

OTHER PUBLICATIONS

Infection and Immunity 64: 3833-3844.*
J.B.C. 1996, vol. 271, 29446-29452.*
J.B.C. 1997 vol. 272, No. 41, Issue of pp. 25678-25684.*
Infection and Immunity 1996, 64: 1054-1059.*
Vaccine 2002, 20, 2263-2277.*
Vaccine 2003, 21, 1650-1657.*
Parasite Immunology 2003, 25, 17-25.*
Vaccine 2003, 22, 30-41.*
Abbott et al., 1999, Purification of soluble, stable recombi-
nant *Plasmodium falciparum* AMA from bacteria. American
Journal of Tropical medicine and Hygiene 61, Suppl. p. 298.
Narum et al., 1994. Differential localization of full-length
and processed forms of PF83/AMA-1 and apical membrane
antigen of *Plasmodium falciparum* merozoites. Mol.
Biochem. Parasitol. 67, 59-68.
Kocken et al., 1999. High-level expression of *Plasmodium*
vivax apical membrane antigen 1 (AMA-1) in *Pichia*
pastoris: strong immunogenicity in Macaca mulatta immu-
nized with *P. vivax* AMA-1 and adjuvant SBAS2. Infec.
Immun. 67, No. 1, pp. 43-49.
Narum et al., 1993. Ion-exchange-immunoaffinity purifica-
tion of a recombinant baculovirus *Plasmodium falciparum*
apical membrane antigen P183/AMA-1. J. Chromatogra-
phy 657, 357-363.
Dutta, et al. 2002. Purification, characterization, and
immunogenicity of the refolded ectodomain of the
Plasmodium falciparum apical membrane antigen 1
expressed in *Escherichia coli*. Infection and Immunity 70,
3101-3110.

* cited by examiner

Primary Examiner—Lynette R. F. Smith

Assistant Examiner—Padma Baskar

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57) **ABSTRACT**

In this application is described the expression and purifica-
tion of a recombinant *Plasmodium falciparum* (3D7)
AMA-1 ectodomain. The method of the present invention
produces a highly purified protein which retains folding and
disulfide bridging of the native molecule. The recombinant
AMA-1 is useful as a diagnostic reagent, for use in antibody
production, and as a vaccine.

15 Claims, 7 Drawing Sheets